Published in Cancer Res on August 01, 2003
Myc proteins as therapeutic targets. Oncogene (2010) 1.88
MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer (2010) 1.72
Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res (2010) 1.57
Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis (2013) 1.30
Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A (2009) 1.27
Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn (2005) 1.23
The impact of MECP2 mutations in the expression patterns of Rett syndrome patients. Hum Genet (2004) 1.21
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res (2008) 1.17
Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One (2009) 1.15
MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res (2010) 1.09
Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia (2005) 1.01
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J (2011) 0.98
A robust method for estimating gene expression states using Affymetrix microarray probe level data. BMC Bioinformatics (2010) 0.96
Gene profiling of high risk neuroblastoma. World J Surg (2005) 0.94
Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status. BMC Med Genomics (2011) 0.91
Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer (2009) 0.91
Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis. PLoS One (2009) 0.85
Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. Am J Pathol (2007) 0.85
Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling. PLoS One (2014) 0.82
Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours. Br J Cancer (2006) 0.76
William L Gerald, M. D., Ph.D., 1954-2008. J Mol Diagn (2009) 0.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 3.27
Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci U S A (2013) 3.06
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Analyzing Recurrent Event Data With Informative Censoring. J Am Stat Assoc (2001) 2.93
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A (2007) 2.85
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol (2005) 2.37
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 2.31
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol (2010) 2.27
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood (2004) 2.12
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol (2004) 2.06
Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol (2003) 2.05
Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol (2004) 2.00
Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models. J Am Stat Assoc (2009) 1.95
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer (2006) 1.89
Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol (2002) 1.88
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res (2003) 1.81
Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell (2002) 1.80
Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol (2004) 1.80
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78
Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia (2005) 1.75
Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab (2006) 1.74
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood (2003) 1.74
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell (2011) 1.74
Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A (2009) 1.72
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol (2009) 1.61
Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan. Leuk Res (2005) 1.59
Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol (2004) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res (2006) 1.56
Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients. Pediatr Blood Cancer (2006) 1.55
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (2015) 1.55
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol (2008) 1.54
Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol (2003) 1.54
Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis (2010) 1.53
Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer (2005) 1.53
Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release (2006) 1.52
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res (2009) 1.50
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer (2009) 1.49
Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol (2005) 1.49
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J (2002) 1.46
Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood Cancer (2005) 1.45
Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol (2010) 1.44
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res (2010) 1.43
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. Pediatr Blood Cancer (2008) 1.43
Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. J Pediatr Hematol Oncol (2003) 1.43
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res (2008) 1.42
Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. Med Pediatr Oncol (2003) 1.41
Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol (2003) 1.40
Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest (2007) 1.40